Vir Biotechnology (VIR) Current Leases (2019 - 2023)

Vir Biotechnology (VIR) posted Current Leases of $7.3 million for Q1 2023, up 75.68% sequentially from $4.1 million in Q4 2022.

Vir Biotechnology (VIR) Current Leases (2019 - 2023) Analysis & Trends

Vir Biotechnology has reported Current Leases for 4 years, with the latest figure at $7.3 million in Q1 2023.

Quarterly Current Leases changed N/A year-over-year to $7.3 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $7.3 million (changed N/A YoY) and the FY2022 annual result came in at $4.1 million, changed N/A from the prior year.
Current Leases grew to $7.3 million in Q1 2023 per VIR's latest filing, from $4.1 million in the prior quarter.
Over five years, Current Leases peaked at $7.3 million in Q1 2023 and troughed at $200000.0 in Q1 2020.
A 4-year average of $1.8 million and a median of $300000.0 in 2020 frame the typical range for Current Leases.
The widest YoY moves for Current Leases: up 26.58% in 2020, down 26.58% in 2020.
Over 4 years, Current Leases stood at $237000.0 in 2019, then climbed by 26.58% to $300000.0 in 2020, then soared by 1279.0% to $4.1 million in 2022, then jumped by 75.68% to $7.3 million in 2023.
According to Business Quant data, Current Leases over the past three periods registered $7.3 million, $4.1 million, and $300000.0 for Q1 2023, Q4 2022, and Q4 2020 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	11.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	16.75 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	21.95 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	2.24 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	45.93 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.27 Mn
10	Vir Biotechnology	1.56 Bn	1.56 Bn	238.95 Mn	-

Download Data